Psychosis in Parkinson’s and Alzheimer’s Disease Market Analysis 2034 – Competitive Landscape, Clinical Trials, Market Share, Therapies, Prevalence, and Key Players by DelveInsight

Psychosis in Parkinson’s and Alzheimer’s Disease Market

DelveInsight has launched a new report on “Psychosis in Parkinson’s and Alzheimer’s Disease – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Psychosis in Parkinson’s and Alzheimer’s Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson’s and Alzheimer’s Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

According to DelveInsight’s analysis, the psychosis in Parkinson’s disease and Alzheimer’s disease market in the 7MM was valued at approximately USD 1,290 million in 2023 and is projected to grow over the forecast period from 2024 to 2034.

Emerging therapies for psychosis in Parkinson’s and Alzheimer’s disease, including NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others, are expected to drive significant growth in the market in the coming years.

Gain exclusive access to detailed forecasts, emerging therapies, and competitive intelligence shaping the Psychosis in Parkinson’s and Alzheimer’s Disease Market

Some of the key facts of the Psychosis in Parkinson’s and Alzheimer’s Disease Market Report:

• According to DelveInsight, the psychosis market in Parkinson’s disease and Alzheimer’s disease across the seven major markets (7MM) was valued at approximately USD 1.29 billion in 2023 and is expected to grow steadily over the forecast period from 2024 to 2034.
• In 2023, the total number of diagnosed Parkinson’s disease cases in the 7MM was estimated at 2.6 million, with the United States accounting for about 45% of these cases. The EU4 (France, Germany, Italy, and Spain) and the UK together also represented roughly 45%, while Japan contributed around 10%. The prevalence of Parkinson’s disease is projected to rise by 2034.
• During the same year, an estimated 6.9 million diagnosed cases of psychosis associated with Parkinson’s and Alzheimer’s disease were reported in the 7MM. Among these, the United States accounted for 34%, Japan nearly 31%, and Germany around 11%.
• The market for psychosis in these neurodegenerative diseases is expected to expand, driven by the launch of innovative therapies. Key emerging treatments include KarXT (xanomeline-trospium) by Karuna Therapeutics, Ulotaront (SEP-363856) by Sunovion Pharmaceuticals, and ITI-1284 by Intra-Cellular Therapies.
• With the aging population growing, the prevalence of Parkinson’s and Alzheimer’s disease is expected to increase, fueling demand for effective psychosis treatments. Greater awareness of psychosis as a significant symptom may lead to earlier diagnosis and better management, further supporting market growth.
• However, substantial unmet needs remain. The lack of curative therapies and reliable biomarkers makes early diagnosis and treatment challenging. Existing screening tools are often complex, and while NUPLAZID (pimavanserin) is approved for psychosis in Parkinson’s disease, there is no FDA-approved treatment for psychosis in Alzheimer’s disease, highlighting a critical gap. Additionally, psychosis symptoms are often underreported or misattributed, causing delays in care and inaccuracies in epidemiological data.
• Key companies actively developing therapies in this space include Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others. Promising pipeline candidates include NUPLAZID, Ulotaront, KarXT, ITI-1284, among others.
• In May 2023, the FDA approved Rexulti (brexpiprazole) for treating agitation associated with dementia due to Alzheimer’s disease. This marked the first FDA-approved therapy addressing restlessness and aggression in Alzheimer’s patients. Clinical trials showed that patients receiving 2 mg or 3 mg of Rexulti experienced significant symptom improvements compared to placebo, with common side effects including headache, dizziness, urinary tract infections, and sleep disturbances.

Psychosis in Parkinson’s and Alzheimer’s Disease Overview

Psychosis in Parkinson’s and Alzheimer’s disease manifests as hallucinations and delusions, significantly impacting patient quality of life. In Parkinson’s disease, psychosis affects 20-70% of patients, often emerging in later stages due to disease progression and dopaminergic treatment effects. Symptoms include visual hallucinations, paranoid delusions, and minor sensory disturbances, usually with preserved sensorium. In Alzheimer’s disease, psychosis also presents as delusions and hallucinations, commonly linked to cognitive decline and neurodegeneration. Both conditions pose clinical challenges, as psychosis can worsen disease outcomes, complicate management, and increase caregiver burden. Treatment requires balancing control of psychotic symptoms while minimizing motor or cognitive side effects.

Get a complimentary preview of DelveInsight’s latest findings on the Psychosis in Parkinson’s and Alzheimer’s Disease Market (2020–2034) @ Psychosis in Parkinson’s and Alzheimer’s Disease Market Forecast

Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology

In 2023, the diagnosed prevalent cases of Parkinson’s disease (PD) in the seven major markets (7MM) totaled approximately 2.6 million, with the US and combined EU4 plus UK each accounting for about 45%, and Japan representing 10%. Germany led among EU4 countries with 487,000 cases. Age-specific PD cases in EU4 and the UK showed the highest prevalence in those aged 70 and above. Alzheimer’s disease (AD) affected 6.3 million diagnosed individuals in the US in 2023, with females representing 65% of cases. In Japan, 2.1 million AD patients experienced psychosis, growing at a CAGR of 1.9%, whereas PD psychosis cases numbered 37,000. Trends indicate a rising burden of both diseases by 2034.

Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology Segmentation:

• Diagnosed Prevalent Cases of Parkinson’s disease
• Diagnosed Prevalent Cases of Alzheimer’s disease
• Gender-specific Cases of Parkinson’s disease
• Gender-specific Cases of Alzheimer’s disease
• Age-specific Cases of Parkinson’s disease
• Age-specific Cases of Alzheimer’s disease
• Diagnosed Prevalent Cases of Psychosis in Parkinson’s disease
• Diagnosed Prevalent Cases of Psychosis in Alzheimer’s disease

Key benefits of the Psychosis in Parkinson’s and Alzheimer’s Disease market report:

1. Psychosis in Parkinson’s and Alzheimer’s Disease market report covers a descriptive overview and comprehensive insight of the Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology and Psychosis in Parkinson’s and Alzheimer’s Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Psychosis in Parkinson’s and Alzheimer’s Disease market report provides insights on the current and emerging therapies.
3. Psychosis in Parkinson’s and Alzheimer’s Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Psychosis in Parkinson’s and Alzheimer’s Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psychosis in Parkinson’s and Alzheimer’s Disease market.

Got queries? Click here to know more about the Psychosis in Parkinson’s and Alzheimer’s Disease Market Landscape.

Psychosis in Parkinson’s and Alzheimer’s Disease Market Outlook

The psychosis market in Parkinson’s and Alzheimer’s disease across the seven major markets (7MM) was valued at approximately USD 1.29 billion in 2023 and is expected to grow steadily through 2034. The US dominated the market with around USD 868 million in revenue, driven by increased disease awareness and treatment advancements. The EU4 and UK combined contributed about USD 219 million, representing nearly 17% of the total 7MM market, with Germany leading in revenue followed by Italy and the UK. In the US, NUPLAZID held the largest market share among therapies, generating approximately USD 562 million in 2023. This growth is fueled by rising diagnosed cases, evolving therapeutic options, and heightened focus on psychosis associated with these neurodegenerative diseases.

Psychosis frequently occurs in individuals with Alzheimer’s disease and often persists throughout the course of the illness. Studies indicate that over half of Alzheimer’s patients will experience psychotic symptoms at some point during their disease progression.

Antipsychotic medications remain the primary treatment for managing psychotic episodes, with drug choice, dosage, and administration tailored to the specific condition. Alongside pharmacological therapy, caregivers and family members play a vital role in managing psychosis by providing a safe and supportive environment. Cognitive behavioral therapy (CBT) is also commonly recommended as an initial intervention for individuals exhibiting psychotic symptoms.

Although standardized treatment guidelines are limited, pimavanserin (34 mg/day) is considered first-line therapy for Parkinson’s disease psychosis, as it is the only FDA-approved drug for this condition and has a low risk of severe adverse effects. If pimavanserin is unavailable or ineffective, clozapine (up to 50 mg/day) or quetiapine (titrated up to 150 mg/day) may be used. However, quetiapine may not fully control psychotic symptoms in some patients, while clozapine carries the risk of agranulocytosis and requires regular blood monitoring.

There is a pressing need for more effective and targeted therapies for psychosis in both Alzheimer’s and Parkinson’s disease, as current treatments are often limited by side effects such as hallucinations, confusion, and nausea. With no FDA-approved therapy for Alzheimer’s disease psychosis, developing precise risk profiles and optimizing the use of existing antipsychotics remain critical objectives.

To address these unmet needs, several late-stage drug candidates are under development. These include KarXT (xanomeline-trospium) by Karuna Therapeutics, Ulotaront (SEP-363856) by Sunovion Pharmaceuticals, and FANAPT (iloperidone), all of which show promise in expanding treatment options for psychosis associated with neurodegenerative diseases.

Psychosis in Parkinson’s and Alzheimer’s Disease Competitive Landscape

Psychosis in Parkinson’s and Alzheimer’s Disease Marketed Drugs

• NUPLAZID (pimavanserin): Acadia Pharmaceuticals

Psychosis in Parkinson’s and Alzheimer’s Disease Emerging Drugs

• Ulotaront (SEP-363856): Sunovion Pharmaceuticals
• KarXT (xanomeline-trospium): Karuna Therapeutics
• ITI-1284: Intra-Cellular Therapies

Our experts can help you explore pipeline dynamics, key players, and growth drivers @ Psychosis in Parkinson’s and Alzheimer’s Disease Drugs and Companies

Psychosis in Parkinson’s and Alzheimer’s Disease Market Drivers

• Rising Prevalence: Increasing diagnosed cases of Parkinson’s and Alzheimer’s diseases globally contribute to higher psychosis incidence, fueling demand for effective treatments.
• Advancements in Treatment: Innovative drugs, such as NUPLAZID, and emerging therapies specifically targeting psychosis symptoms are expanding treatment options and market potential.
• Growing Awareness: Enhanced disease recognition by healthcare providers and caregivers leads to improved diagnosis and management of psychosis in neurodegenerative conditions.
• Aging Population: The global increase in elderly populations, who are more susceptible to Parkinson’s and Alzheimer’s, escalates the need for psychosis management.
• Regulatory Support: Favorable regulatory policies facilitate faster approvals and adoption of novel psychosis treatments.

Psychosis in Parkinson’s and Alzheimer’s Disease Market Barriers

• Complex Disease Mechanisms: Psychosis symptoms in Parkinson’s and Alzheimer’s diseases are multifactorial, complicating drug development and treatment effectiveness.
• Safety Concerns: Side effects and tolerability issues related to antipsychotic therapies restrict widespread use, especially in frail elderly patients.
• Limited Treatment Options: Despite progress, few FDA-approved therapies specifically target psychosis in these diseases, limiting clinicians’ choices.
• High Treatment Costs: The expense of novel therapies can impede patient access, particularly in lower-income regions.
• Diagnostic Challenges: Overlapping symptoms with other neuropsychiatric disorders can delay accurate diagnosis and appropriate treatment initiation.

Identify high-potential opportunities, assess emerging competitors, and make informed decisions for 2025-2034 @ Psychosis in Parkinson’s and Alzheimer’s Disease Clinical Trials and FDA Approvals

Scope of the Psychosis in Parkinson’s and Alzheimer’s Disease Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Psychosis in Parkinson’s and Alzheimer’s Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others
• Key Psychosis in Parkinson’s and Alzheimer’s Disease Therapies: NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others
• Psychosis in Parkinson’s and Alzheimer’s Disease Therapeutic Assessment: Psychosis in Parkinson’s and Alzheimer’s Disease current marketed and Psychosis in Parkinson’s and Alzheimer’s Disease emerging therapies
• Psychosis in Parkinson’s and Alzheimer’s Disease Market Dynamics: Psychosis in Parkinson’s and Alzheimer’s Disease market drivers and Psychosis in Parkinson’s and Alzheimer’s Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Psychosis in Parkinson’s and Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Psychosis in Parkinson’s and Alzheimer’s Disease Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Psychosis in Parkinson’s and Alzheimer’s Disease Patient Share (%) Overview at a Glance

5. Psychosis in Parkinson’s and Alzheimer’s Disease Market Overview at a Glance

6. Psychosis in Parkinson’s and Alzheimer’s Disease Disease Background and Overview

7. Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Psychosis in Parkinson’s and Alzheimer’s Disease

9. Psychosis in Parkinson’s and Alzheimer’s Disease Current Treatment and Medical Practices

10. Unmet Needs

11. Psychosis in Parkinson’s and Alzheimer’s Disease Emerging Therapies

12. Psychosis in Parkinson’s and Alzheimer’s Disease Market Outlook

13. Country-Wise Psychosis in Parkinson’s and Alzheimer’s Disease Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Psychosis in Parkinson’s and Alzheimer’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading business consulting and market research company focused on the healthcare and life sciences sectors, providing comprehensive market intelligence, competitive landscape analysis, and strategic insights to support decision-making across the pharmaceutical industry.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services